Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuation, with its stock trading at 3.0x trailing revenues, compared to 3.6x for MRK stock.

Here's A Better Pharmaceutical Pick Over Merck Stock

Merck & Co., Inc. (MRK) CEO Rob Davis Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

Absci Corp

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.

Absci (ABSI) Inks Research Agreement With Merck, Stock Up

Merck & Co Inc (NYSE: MRK) has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, met one of its dual primary endpoints in NSCLC patients following surgical resection regardless of PD-L1 expression. Adjuvant treatment with Keytruda resulted in a statistically significant and clinically meaningful improvement in disease-free survival (DFS) compared with placebo in stage IB-IIIA non-small cell lung cancer (NSCLC).

Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Showed Significant Improvement in Disease-Free Survival as Adjuvant Treatment for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression

Merck's KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

Caterpillar

Celsius Holdings

Cisco Systems

Chevron

Dow Inc

Intel

Intrepid Potash

Tidewater

Trillium Therapeutics

Verizon

Winnebago

Two sample Breakout Stocks for Week 2 with better than 10% short-term upside potential and a Dow stock pick. This past week, 3 stocks beat 10% peak gains with RES +29.2%, UGRO +11.0%, and DYAI +10.2% with Momentum Gauge® values still high negative.

Week 2 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge

AstraZeneca

Bristol-Myers

Eli Lilly

Some of the world's biggest drugmakers have important dates with the FDA coming up soon.

3 Big FDA Approvals to Watch For in Q1 2022

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3

Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3

Absci Corporation (NASDAQ: ABSI) went up 50% after it announced that it had executed a research and collaboration agreement with Merck, commonly referred to as MSD outside Canada and the US. The company came to this agreement via its AI-powered Integrated Drug Creation Platform.

Absci Corp up 50% after announcing research collaboration with Merck

British American Tobacco

Imperial Brands PLC

Roche Holding AG

Sanofi

T. Rowe Price Group

Western Union

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The January 2022 Heat Map

McDonald's

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

These Dow stocks provide investors with safe and growing payouts at reasonable valuations.

3 Dow Stocks to Buy Hand Over Fist in January

Amgen

Boeing

Disney

Honeywell

Visa

Walmart

"There are a few comeback stories in the dogs of the Dow, but for the most part I don't expect these dogs to have their day in 2022," the "Mad Money" host said.

Jim Cramer's 2022 forecast for3M

Arrow Financial

SPDR Dow Jones Industrial Average ETF

First Merchants

General Motors

Nokia

TreeHouse Foods

Zimmer Biomet Hlds

To find solid independent market analysis and investment ideas, I like to regularly consult those unsung market heroes — stock newsletter writers.

Why the bull market will stay alive in 2022 — plus 8 cheap stocks for your money now

Coca-Cola

Walgreens

The decades-old income-and-value strategy, the Dogs of the Dow, will try to bounce back in 2022. Here are this year's 10 members.

Dogs of the Dow 2022: 10 Dividend Stocks to Watch

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference

Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Labs

India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, reported Reuters. A company spokesperson said Reddy's would launch the molnupiravir generic at ₹35 ($0.4693) per capsule.

Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters

This article focuses on the margin stability of Merck & Co. Its marginal efficiency of capital, a key indicator for its future profitability, has been under some pressure.

Merck & Co.: Attractive Valuation With Margin Stability In Focus

Here are the newest stocks to join the portfolio for those using this easy-to-follow strategy.

Meet the 2022 Dogs of the Dow

American Electric Power Company

Allstate

Air Products and Chemicals

Best Buy

Bank of New York Mellon

Comcast

JPMorgan Chase & Co

L3Harris

Lockheed Martin

PACCAR

Snap-on

Texas Instruments

U.S. Bancorp

Using five stringent stock selection criteria and two additional screens, I found sixteen dividend growth stocks suitable for further research and possible investment in 2022. The criteria consider Stock Quality, Stock Valuation, Growth Outlook, Income Outlook, and Dividend Safety. I also screen by dividend increase streak and using a popular performance metric.

My Top 16 Dividend Growth Stock Picks For 2022

I list my 3 top-quality dividend growth stocks for 2022. The reasons why these stocks may be attractive to investors in 2022 are examined closely. I discuss the dividend safety and valuation of all three dividend growth stocks.

Top 3 Dividend Growth Stocks For 2022

Dyadic International Inc., DE

Enphase Energy

Procter & Gamble

Urban-gro

Two sample Breakout Stocks for Week 1 with better than 10% short-term upside potential and a Dow stock pick. This past week 1 stock beat 10% peak gains with AEHR +27.2% and METC +8.6% with Momentum Gauge® values still negative.

Week 1 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge

News for Merck Stock (MRK)